<unk>  (also<unk>  tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy. Originally introduced in 1959 for the treatment of hypertension. Its use as an antiarrhythmic for ventricular fibrillation was discovered and patented by Marvin Bacaner in 1969 at the University of Minnesota. The American Heart Association removed<unk>  from their 2000 ECC/ACC guidelines due to its unproven efficacy and ongoing supply problems. Many have cited these supply problems as an issue of raw materials needed in the production of<unk> . By the release of the AHA 2005 ECC/ACC guidelines there is no mention of<unk>  and it is virtually unavailable throughout most of the world. On June 8, 2011<unk>  tosylate was announced as unavailable in the US after request of Hospira Inc. to withdraw its NDA from the market.<unk>  will remain on the FDA's discontinued drug list since its withdrawal was not the result of a safety or effectiveness concern. In mid 2019, it was reintroduced.
Bretylium
Toremifene
Desomorphine
Tasimelteon
Zaleplon
Bocasan
Patiromer
Tiotixene